RE: Half-year Report6 Aug 2021 15:48
Never has a stock been so unloved as Hikma - and yet they keep on performing well - Generic Advair achievement is world leading by the way and a licence to print money - and now excellent results, yet a 6% price drop! Due to their continued and reliable performance, and with Biden in power bloating US health spending - I am happy to take the pain based on their solid track record and clear delivery on signposted strategy.